From the ∗Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi
†Department of Neuropsychiatry, Kyorin University School of Medicine
‡Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Received for publication February 9, 2022; accepted April 1, 2022.
Reprints: Takefumi Suzuki, MD, PhD, Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, 1110, Shimokato, Chuo-city, Yamanashi, 409-3898, Japan (e-mail: [email protected]).
K.Y. has received manuscript or speaker's fees from Dainippon Sumitomo Pharma; Eisai; Ishiyaku Publishers, Inc; Mochida Pharmaceutical; and Otsuka Pharmaceutical. T.S. has received manuscript or speaker's fees from Astellas, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Kyowa Yakuhin, Lundbeck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Nihon Medi-Physics, Novartis, Otsuka Pharmaceutical, Shionogi, Shire, Takeda Pharmaceutical, Tsumura, Wiley Japan, and Yoshitomi Yakuhin and research grants from Dainippon Sumitomo Pharma, Eisai, Mochida Pharmaceutical, Meiji Seika Pharma, and Shionogi. The other authors have no conflicts of interest or financial disclosures to report.
